Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of Research and Development
February 12, 2018 17:30 ET
|
Arcturus Therapeutics, Inc.
Dr. Pad Chivukula Resigns as Chief Scientific Officer and Chief Operating Officer SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines...
Arcturus Therapeutics Issues Statement
February 06, 2018 23:09 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today issued the following statement in response to the 13D filing issued by...
Arcturus Therapeutics Appoints Mark Herbert as Interim President
February 02, 2018 08:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced that Mark R. Herbert, Vice President of Business Development...
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
January 30, 2018 23:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd., or Arcturus (NASDAQ:ARCT), an RNA medicines company, today announced that it will hold an extraordinary general meeting of...
Arcturus Therapeutics Announces Expansion of Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH) and Other GI Disorders
January 17, 2018 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, announced today that it is extending its partnership with Takeda...
Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market
November 16, 2017 07:00 ET
|
Arcturus Therapeutics, Inc.
Combined Company Commences Trading on the Nasdaq Global Market on November 16, 2017 under the Ticker Symbol “ARCT”Approximately $50.1 Million in Net Cash Following Closing of the MergerTen (10)...
Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7
November 02, 2017 08:01 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it will host a live R&D webcast focused on the “Advances in...
Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics
October 31, 2017 07:59 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research...
Arcturus Therapeutics Announces Presentations at Conferences in November
October 26, 2017 08:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it plans to present at three conferences in November 2017: the 5th...
Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines
October 19, 2017 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license...